Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations

With improvement in the understanding of the pathophysiological mechanisms of heart failure with reduced ejection fraction (HFrEF), several drug classes have been developed targeting the renin–angiotensin–aldosterone system, the beta adrenergic system, and to a certain extent the nitric oxide pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kassis-George, Hayah, Verlinden, Nathan J, Fu, Sheng, Kanwar, Manreet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977472/
https://www.ncbi.nlm.nih.gov/pubmed/35386181
http://dx.doi.org/10.2147/TCRM.S357422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977472/
https://www.ncbi.nlm.nih.gov/pubmed/35386181
http://dx.doi.org/10.2147/TCRM.S357422

Ejemplares similares